ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

SILO Silo Pharma Inc

1.12
-0.09 (-7.44%)
2024年6月15日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Silo Pharma Inc SILO NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.09 -7.44% 1.12 13:00:10
始値 安値 高値 終値 前日終値
1.26 1.06 1.26 1.10 1.21
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/6/1406:08EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2024/6/1402:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/1205:00EDGAR2Form D - Notice of Exempt Offering of Securities
2024/6/0721:18GLOBESilo Pharma Announces Successful Production of its SP-26..
2024/6/0705:52EDGAR2Form 8-K - Current report
2024/6/0705:50GLOBESilo Pharma Announces Closing of $2 Million Registered..
2024/6/0619:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/6/0521:00GLOBESilo Pharma Announces $2 Million Registered Direct Offering..
2024/6/0505:05EDGAR2Form 8-K - Current report
2024/6/0421:41GLOBESilo Pharma Submits Pre-Investigational New Drug Application..
2024/5/2121:45GLOBESilo Pharma Announces Positive Results from Study for..
2024/5/1421:45GLOBESilo Pharma to Participate in FDA Meeting Exploring Emerging..
2024/5/1405:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/4/2321:15GLOBESilo Pharma Announces Positive Results for Intranasal PTSD..
2024/4/1021:11GLOBESilo Pharma set to Acquire Exclusive Licensing for Promising..
2024/3/2021:30GLOBESilo Pharma Exercises Option for Exclusive License Agreement..
2024/3/1820:15GLOBESilo Pharma Files Patent for Groundbreaking Ketamine Implant..
2024/2/2822:25GLOBESilo Pharma Completes Successful Dose-Ranging Study of..
2024/2/1422:45GLOBESilo Pharma’s SP-26 Ketamine Implant Demonstrates Successful..
2024/2/0203:15EDGAR2Form 8-K - Current report
2024/2/0200:00GLOBESilo Pharma Announces Pipeline Prioritization for 2024..
2024/1/2607:29EDGAR2Form S-3/A - Registration statement under Securities Act of..
2024/1/2607:27EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/1/2422:55GLOBESilo Pharma Announces Positive Results in Alzheimer’s..
2024/1/2407:01EDGAR2Form S-3 - Registration statement under Securities Act of..
2024/1/1202:15EDGAR2Form 8-K/A - Current report: [Amend]
2024/1/1006:30EDGAR2Form 8-K - Current report
2024/1/0422:55GLOBESilo Pharma Successfully Completes First Phase of..
2023/12/2822:25GLOBESilo Pharma and Partner Receive Regulatory Approval to Begin..
2023/12/2206:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2106:58EDGAR2Form 8-K12B - Notification that a class of securities of..
2023/12/1909:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1206:05EDGAR2Form 8-K - Current report
2023/12/0808:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0606:05EDGAR2Form 8-K - Current report
2023/12/0506:55EDGAR2Form 8-K - Current report
2023/12/0111:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/2807:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/2306:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/2122:01GLOBESilo Pharma Enters into Exclusive License Agreement with..
2023/11/2109:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/1407:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0822:11GLOBESilo Pharma to Initiate Dose-Ranging Study of Novel..
2023/10/2406:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/10/2406:00EDGAR2Form DEF 14A - Other definitive proxy statements
2023/10/1621:11GLOBESilo Pharma’s SPU-21 Peptide Shows Positive Results Against..
2023/10/1121:35GLOBESilo Pharma Initiates Human Factor Study of SPC-15 for the..
2023/10/1105:00EDGAR2Form PRE 14A - Other preliminary proxy statements
2023/9/2021:28GLOBESilo Pharma Announces Positive Data on SPC-15 for PTSD and..
2023/9/1221:50GLOBESilo Pharma Initiates Feasibility Study of SPC-15 Novel..